UK markets closed
  • FTSE 100

    -63.84 (-0.91%)
  • FTSE 250

    +26.10 (+0.11%)
  • AIM

    +3.60 (+0.28%)

    -0.0007 (-0.06%)

    -0.0059 (-0.43%)

    -490.40 (-1.39%)
  • CMC Crypto 200

    -32.05 (-2.62%)
  • S&P 500

    -40.76 (-0.91%)
  • DOW

    -166.44 (-0.48%)

    -0.65 (-0.90%)

    -2.80 (-0.16%)
  • NIKKEI 225

    +176.71 (+0.58%)

    +252.91 (+1.03%)
  • DAX

    -161.58 (-1.03%)
  • CAC 40

    -52.40 (-0.79%)

World Psoriatic Arthritis Epidemiology Forecasts to 2030: Diagnosed, Gender Specific, Age-Specific and Severity Specific Cases

·5-min read

Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis - Epidemiology Forecast to 2030" drug pipelines has been added to's offering.

The etiology and pathogenesis of PsA involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33-50% of psoriatic arthritis patients have at least one first-degree relative who also has psoriasis or PsA. Genes associated with PsA include those in the HLA region involved in antigen presentation and immune recognition and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression and signaling, and T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma is known to induce flares of psoriatic skin lesions known as the Koebner phenomenon. There is evidence the joint trauma may induce a flare of arthritis, referred to as the "internal" or "deep" Koebner phenomenon.

PsA shares some clinical features with other inflammatory arthritides, including rheumatoid arthritis (RA), reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnose. Unlike PsA, RA tends to be symmetrical and generally spares the DIP joints. AS has an earlier age of onset compared to psoriatic arthritis, and sacroiliac involvement is usually symmetric rather than asymmetric.

There are no laboratory tests that are specific for PsA. Acute phase reactants such as ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) may become elevated as in most inflammatory diseases. However, a normal ESR and CRP should not be used to rule out a diagnosis of PsA as these levels increase in only about 40% of patients. Besides, imaging plays a central role. Classical radiography has been used for this purpose for over 100 years. It allows identifying the late stages of the disease when bone tissue is affected. In the last 20 years, many new imaging modalities, such as ultrasonography (US), computed tomography (CT), and magnetic resonance (MR), have been developed and became important diagnostic tools for the evaluation of rheumatoid diseases. They enable the assessment and monitoring of early inflammatory changes. As a result, patients have earlier access to modern treatment, and thus the formation of destructive changes in joints can be markedly delayed or even avoided.

PsA may range from mild to severe, and it is crucial to treat it no matter the severity. If left untreated, PsA can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating PsA may also help reduce inflammation in the body, leading to other diseases. These other diseases are often referred to as comorbidities. However, at present, no cure for PsA exists, so treatment goals are to slow disease progression, improve quality of life, lessen pain, and preserve the range of motion. In most patients with PsA, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs if a patient does not adequately respond.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent cases of Psoriatic Arthritis, Diagnosed cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, Age-specific cases of Psoriatic Arthritis and Severity-specific Prevalence of Psoriatic Arthritis. The report includes the prevalent scenario of Psoriatic Arthritis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Scope of the Report

  • It covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.

  • The Psoriatic Arthritis Epidemiology Report and Model provide an overview of the risk factors and global trends of Psoriatic Arthritis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

  • It provides insight into the historical and forecasted patient pool of Psoriatic Arthritis in seven major markets covering the United States, EU5 and Japan

  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.

  • The report assesses the disease risk and burden and highlights the unmet needs of Psoriatic Arthritis.

  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by total prevalent cases of Psoriatic Arthritis in the 7MM.

  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by diagnosed cases of Psoriatic Arthritis in the 7MM.

  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by gender-specific cases of Psoriatic Arthritis in the 7MM.

  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by age-specific cases of Psoriatic Arthritis in the 7MM.

  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by the severity-specific prevalence of Psoriatic Arthritis in the 7MM.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Psoriatic Arthritis Market Overview at a Glance

4. Executive Summary of Psoriatic Arthritis

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Organizations contributing towards Psoriatic arthritis (PsA)

8. Patient Journey

9. Case Reports

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting